Veracyte: Core Growth Funds Prosigna And TrueMRD (NASDAQ:VCYT)
· seekingalpha.com
Veracyte (VCYT) Q2 2026 shows strong revenue/EBITDA growth, cash flow, and upside from Prosigna/TrueMRD. Explore valuation, moat, and guidance.
I believe Veracyte ( VCYT ) is now transitioning from a 2-product genomic testing business into a self-funded cancer diagnostic platform. The company's clinical...